CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

HEPATITIS C PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on
Hepatitis C
Literature Review, March 2015

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES

Liver fibrosis progression in hepatitis C virus infection after seroconversion. Butt AA1, Yan P2, Lo Re V 3rd3, et al. JAMA Intern Med. 2015 Feb 1;175(2):178-85. doi: 10.1001/jamainternmed.2014.6502.

Risk of infections during interferon-based treatment in patients with chronic HCV infection and advanced hepatic fibrosis. Maan R1, van der Meer AJ, Hansen BE, et al. J Gastroenterol Hepatol. 2015 Feb 13. doi: 10.1111/jgh.12929. [Epub ahead of print]

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. Jensen D1, Sherman KE2, Hézode C3, et al. J Hepatol. 2015 Feb 19. pii: S0168-8278(15)00125-7. doi: 10.1016/j.jhep.2015.02.018. [Epub ahead of print]

Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. Hulskotte EG1, Bruce RD, Feng HP, et al. Eur J Clin Pharmacol. 2015 Mar;71(3):303-11. doi: 10.1007/s00228-014-1789-4. Epub 2015 Feb 11.

Integrated Care Increases Treatment and Improves Outcomes of Patients with Chronic HCV Infection and Psychiatric Illness or Substance Abuse. Ho SB1, Bräu N2, Cheung R3, et al. Clin Gastroenterol Hepatol. 2015 Feb 24. pii: S1542-3565(15)00161-5. doi: 10.1016/j.cgh.2015.02.022. [Epub ahead of print]

Neuroimaging abnormalities, neurocognitive function, and fatigue in patients with hepatitis C. Thames AD1, Castellon SA1, Singer EJ1, et al. Neurol Neuroimmunol Neuroinflamm. 2015 Jan 14;2(1):e59. doi: 10.1212/NXI.0000000000000059. eCollection 2015.

The Hepatitis C treatment experience: Patients’ perceptions of the facilitators of and barriers to uptake, adherence and completion. Sublette VA1, Smith SK, George J, McCaffery K, Douglas MW. Psychol Health. 2015 Feb 23:1-18. [Epub ahead of print]

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Tablets for Hepatitis C Virus Genotype 1 Infection. Klibanov OM1, Gale SE2, Santevecchi B2. Ann Pharmacother. 2015 Feb 13. pii: 1060028015570729. [Epub ahead of print]

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Schistosome infection aggravates HCV-related liver disease and induces changes in the regulatory T-cell phenotype. Loffredo-Verde E1, Abdel-Aziz I, Albrecht J, et al. Parasite Immunol. 2015 Feb;37(2):97-104. doi: 10.1111/pim.12171.

AAK1 and GAK Regulate Hepatitis C Virus Entry and Are Potential Drug Targets. Neveu G1, Ziv-Av A1, Barouch-Bentov R1, et al. J Virol. 2015 Feb 4. pii: JVI.02705-14. [Epub ahead of print]

miR-122 Stimulates Hepatitis C Virus RNA Synthesis by Altering the Balance of Viral RNAs Engaged in Replication versus Translation. Masaki T1, Arend KC2, Li Y3, et al. Cell Host Microbe. 2015 Feb 11;17(2):217-28. doi: 10.1016/j.chom.2014.12.014. Epub 2015 Feb 5.

Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/ founder genotypes 1, 3, and 4. Stoddard MB1, Li H1, Wang S1, et al. MBio. 2015 Feb 24;6(2). pii: e02518-14. doi: 10.1128/mBio.02518-14.

Transmitted/Founder Hepatitis C Viruses Induce Cell-Type- and Genotype-Specific Differences in Innate Signaling within the Liver. Mitchell AM, Stone AE, Cheng L1, et al. MBio. 2015 Feb 24;6(2). pii: e02510-14. doi: 10.1128/mBio.02510-14.

Alcohol-Induced miR-27a Regulates Differentiation and M2 Macrophage Polarization of Normal Human Monocytes. Saha B1, Bruneau JC1, Kodys K1, Szabo G2. J Immunol. 2015 Feb 25. pii: 1402190. [Epub ahead of print]

Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects. Tanoue S1, Chang LY1, Li Y1, Kaplan DE2. Cell Immunol. 2015 Feb 25;295(1):36-45. doi: 10.1016/j.cellimm.2015.02.008. [Epub ahead of print]

The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection. Wang M1, Li JS, Ping Y, et al. Arch Virol. 2015 Feb 10. [Epub ahead of print]

Influence of Genes Suppressing Interferon Effects in Peripheral Blood Mononuclear Cells during Triple Antiviral Therapy for Chronic Hepatitis C. Iijima S1, Matsuura K2, Watanabe T1, et al. PLoS One. 2015 Feb 23;10(2):e0118000. doi: 10.1371/journal.pone.0118000. eCollection 2015.

HIV/HCV COINFECTION

The Correlation between Hepatitis C Core Antigen and Hepatitis C Virus RNA Levels with Respect to Human Immunodeficiency Virus Status, Hepatitis C Virus Genotype and Interferon-Lambda-4 Polymorphism. Duy Thong V1, Akkarathamrongsin S, Avihingsanon A, et al. Intervirology. 2015;58(2):73-9. doi: 10.1159/000370070. Epub 2015 Feb 13.

Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients. Miailhes P1, Gilbert C, Lacombe K, et al. Liver Int. 2015 Feb 4. doi: 10.1111/liv.12799. [Epub ahead of print]

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Molina JM1, Orkin C2, Iser DM3, et al. Zamora FX4, Nelson M5, Stephan C6, Massetto B7, Gaggar A7, Ni L7, Svarovskaia E7, Brainard D7, Subramanian GM7, McHutchison JG7, Puoti M8, Rockstroh JK9; for the PHOTON-2 study team. Lancet. 2015 Feb 3. pii: S0140-6736(14)62483-1. doi: 10.1016/S0140-6736(14)62483-1. [Epub ahead of print]

Serum Adenosine Deaminase (ADA) Activity: A Novel Screening Test to Differentiate HIV Monoinfection From HIV-HBV and HIV-HCV Coinfections. Abdi M1, Rahbari R, Khatoni Z, Naseri N, Najafi A, Khodadadi I. J Clin Lab Anal. 2015 Feb 16. doi: 10.1002/jcla.21836. [Epub ahead of print]

Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial. Sulkowski MS1, Eron JJ2, et al. JAMA. 2015 Feb 23. doi: 10.1001/jama.2015.1328. [Epub ahead of print]

Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. Osinusi A1, Townsend K2, Kohli A3, et al. JAMA. 2015 Feb 23. doi: 10.1001/jama.2015.1373. [Epub ahead of print]

Risk of Liver Enzyme Elevation during Treatment with Ritonavir-boosted Protease Inhibitors among HIV-monoinfected and HIV/HCV Coinfected Patients. Lapadula G1, Costarelli S, Chatenoud L, et al. J Acquir Immune Defic Syndr. 2015 Feb 26. [Epub ahead of print]

Influence of HCV and HIV on Development of Cryoglobulinemia. Rogalska-Płońska M1, Lapinski TW, Grzeszczuk A, Parfieniuk-Kowerda A, Flisiak R. Viral Immunol. 2015 Feb 27. [Epub ahead of print]

Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. Beste LA1, Green PK, Ioannou GN. Eur J Gastroenterol Hepatol. 2015 Feb;27(2):123-9. doi: 10.1097/MEG.0000000000000241.

Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. Coppola N1, Martini S1, Pisaturo M1, Sagnelli C1, Filippini P1, Sagnelli E1. World J Virol. 2015 Feb 12;4(1):1-12. doi: 10.5501/wjv.v4.i1.1.

Influence of Treatment Complexity on Adherence and Incidence of Blips in HIV/HCV Coinfected Patients. Calvo-Cidoncha E1, González-Bueno J, Almeida-González CV, Morillo-Verdugo R. J Manag Care Spec Pharm. 2015 Feb;21(2):153-7.

COMPLEMENTARY AND ALTERNATIVE MEDICINE

Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro. Jardim AC1, Igloi Z2, Shimizu JF3, et al. Antiviral Res. 2014 Dec 31. pii: S0166-3542(14)00369-6. doi: 10.1016/j.antiviral.2014.12.018. [Epub ahead of print]

Supercritical fluid extraction of heather (Calluna vulgaris) and evaluation of anti-hepatitis C virus activity of the extracts. García-Risco MR1, Vázquez E1, Sheldon J2, et al. Virus Res. 2014 Dec 27. pii: S0168-1702(14)00536-X. doi: 10.1016/j.virusres.2014.12.022. [Epub ahead of print]

EPIDEMIOLOGY, DIAGNOSTICS, AND MISCELLANEOUS WORKS

Correlates of adiponectin in hepatitis C-infected children: the importance of body mass index. Delgado-Borrego A1, Gonzalez-Peralta RP, Raza R, ET AL. J Pediatr Gastroenterol Nutr. 2015 Feb;60(2):165-70. doi: 10.1097/MPG.0000000000000604.

Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Leidner AJ1, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Hepatology. 2015 Feb 11. doi: 10.1002/hep.27736. [Epub ahead of print]

“Test, Listen, Cure” (TLC) Hepatitis C Community Awareness Campaign. Coughlin SS1. JMIR Res Protoc. 2015 Feb 6;4(1):e13. doi: 10.2196/resprot.3822.

Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program. Baxter JD1, Clark RE, Samnaliev M, Aweh G, O’Connell E. Subst Abus. 2015 Feb 23:0. [Epub ahead of print]

Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions. Bruhn R1, Lelie N, Busch M, Kleinman S; the International NAT Study Group. Transfusion. 2015 Feb 27. doi: 10.1111/trf.13024. [Epub ahead of print]

Ethnic differences in presentation and severity of alcoholic liver disease. Levy RE1, Catana AM, Durbin-Johnson B, Halsted CH, Medici V. Alcohol Clin Exp Res. 2015 Mar;39(3):566-74. doi: 10.1111/acer.12660. Epub 2015 Feb 20.

What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments? Rowan PJ1. World J Virol. 2015 Feb 12;4(1):13-6. doi: 10.5501/wjv.v4.i1.13.

Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. Haddad MS1, Zelenev A, Altice FL. J Urban Health. 2015 Feb;92(1):193-213. doi: 10.1007/s11524-014-9924-1.

Implementation of National HIV Screening Recommendations in the Indian Health Service. Reilley B1, Leston J2, Tulloch S3, Neel L4, Galope M5, Taylor M3. J Int Assoc Provid AIDS Care. 2015 Feb 5. pii: 2325957415570744. [Epub ahead of print]

LIVER CANCER

Glycosylation and liver cancer. Mehta A1, Herrera H1, Block T1. Adv Cancer Res. 2015;126:257-79. doi: 10.1016/bs.acr.2014.11.005. Epub 2015 Feb 7.

PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients. Nakaoka K1, Hashimoto S1, Kawabe N1, et al. Springerplus. 2015 Feb 13;4:83. doi: 10.1186/s40064-015-0870-5. eCollection 2015.

Sustained virologic response achieved after curative treatment of HCV-related hepatocellular carcinoma serves as an independent prognostic factor. Kanogawa N1, Ogasawara S, Chiba T, et al. J Gastroenterol Hepatol. 2015 Feb 13. doi: 10.1111/jgh.12925. [Epub ahead of print]

Risk Factors of HCC Development in Non-cirrhotic Patients with Sustained Virologic Response for Chronic HCV Infection. Toyoda H1, Kumada T, Tada T, et al. J Gastroenterol Hepatol. 2015 Feb 13. doi: 10.1111/jgh.12915. [Epub ahead of print]

Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients. Hsu CC1, Goyal A2, Iuga A3, et al. Clin Transl Gastroenterol. 2015 Feb 5;6:e74. doi: 10.1038/ctg.2014.22.

DNA Methylation-based prognosis and epidrivers in hepatocellular carcinoma. Villanueva A1, Portela A, Sayols S, et al. Hepatology. 2015 Feb 2. doi: 10.1002/hep.27732. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)